Amgen and Advaxis finalize ADXS-NEO agreement
Amgen and Advaxis has announced the finalization of a worldwide agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational immunotherapy developed for the treatment of cancer. Read More »
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
                
                
                
                
                
          Alerts Sign-up